Oral Oncology
Volume 39, Issue 7 , Pages 680-686, October 2003

Treatment of squamous cell carcinoma of the anterior faucial pillar–retromolar trigone

Department of Oral and Maxillofacial Surgery, Aristotle University of Thessaloniki, 540 06, Greece

Received 21 February 2003; accepted 25 March 2003.

Abstract 

Cancer of the anterior faucial pillar–retromolar trigone is an uncommon head and neck tumor, which has historically been shown to be associated with poor prognosis. In this retrospective study, we reviewed our experience with primary surgery followed by postoperative radiation therapy in order to determine the impact of our treatment protocols on patients’ outcome. Between January 1994 and December 1998, 31 patients with histologically proven squamous cell carcinoma (SCC) of the anterior faucial pillar–retromolar trigone were treated in our department. Surgical excision of the primary lesion and ipsilateral neck dissection were performed in all patients. Reconstruction was accomplished using masseter muscle flap or tongue flap. Postoperatively, most patients (90%) received radiation therapy (51–58 Gy) to the primary side and neck. Adjuvant chemotherapy was offered if histologic signs of aggressive behavior were identified. Four out of 31 patients were initially seen at stage I or II and 27 patients at stage III or IV of the disease. Metastatic disease was demonstrated in 78% of ipsilateral neck nodes. Occult metastases were found in 64% of clinically N0 necks. The 3-year loco-regional recurrence rates were 44.8%. SCC of retromolar trigone is considered as an aggressive and insidious tumor. The reconstruction of the deficit of the anterior faucial pillar–retromolar area with masseter muscle flap is a reliable, safe and absolutely functional method.

Keywords:  Oral cancer, Retromolar trigone, Anterior faucial pillar

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1368-8375(03)00077-0

doi:10.1016/S1368-8375(03)00077-0

Oral Oncology
Volume 39, Issue 7 , Pages 680-686, October 2003